ARL-17477
ARL-17477
ARL-17477 is a chemical compound that has been studied for its potential pharmacological effects. It is primarily known for its action as a selective inhibitor of the enzyme acetylcholinesterase (AChE), which is responsible for the breakdown of the neurotransmitter acetylcholine in the synaptic cleft. This property makes ARL-17477 of interest in the research of treatments for neurological disorders such as Alzheimer's disease, where acetylcholine levels are typically reduced.
Chemical Structure and Properties[edit | edit source]
ARL-17477 is a synthetic compound with a specific molecular structure that allows it to bind to the active site of acetylcholinesterase. The exact chemical formula and molecular weight of ARL-17477 are proprietary or not widely published, but it is known to belong to a class of compounds that interact with cholinergic systems.
Mechanism of Action[edit | edit source]
ARL-17477 functions by inhibiting acetylcholinesterase, thereby preventing the breakdown of acetylcholine. This leads to an increase in acetylcholine levels in the synaptic cleft, enhancing cholinergic transmission. This mechanism is similar to that of other acetylcholinesterase inhibitors used in clinical practice, such as donepezil and rivastigmine.
Potential Therapeutic Uses[edit | edit source]
The primary therapeutic interest in ARL-17477 lies in its potential application in treating neurodegenerative diseases characterized by cholinergic deficits, such as Alzheimer's disease. By increasing acetylcholine levels, ARL-17477 may help alleviate some of the cognitive symptoms associated with these conditions.
Research and Development[edit | edit source]
Research on ARL-17477 is ongoing, with studies focusing on its efficacy, safety, and pharmacokinetics. Preclinical studies have shown promising results, but further research is needed to determine its potential as a therapeutic agent in humans.
Side Effects and Safety[edit | edit source]
As with other acetylcholinesterase inhibitors, potential side effects of ARL-17477 may include nausea, diarrhea, insomnia, and muscle cramps. The safety profile of ARL-17477 is still under investigation, and it is not yet approved for clinical use.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
